By Fineline Cube 
French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with US-based Earendil Labs to acquire exclusive worldwide rights to two first-in-class bispecific antibodies (BsAbs) targeting autoimmune and inflammatory bowel diseases (IBD). This strategic move underscores Sanofi’s commitment to expanding its portfolio in these therapeutic areas.
Agreement Details
Under the terms of the agreement, Sanofi will gain rights to HXN-1002 and HXN-1003, which were developed using Earendil’s proprietary AI-driven high-throughput discovery platform. Earendil will receive an upfront payment of USD 125 million, with the potential for total payments reaching up to USD 1.72 billion. These payments are contingent upon the achievement of specific development, regulatory, and commercial milestones. Additionally, Earendil is set to receive a USD 50 million near-term milestone payment, along with tiered royalties ranging from high-single-digit to low-double-digit percentages on net sales.
Product Potential
HXN-1002 and HXN-1003 represent significant advancements in the treatment of autoimmune and inflammatory diseases. Their development leverages Earendil’s innovative AI platform, which accelerates the discovery and optimization of novel therapeutic candidates. This partnership positions Sanofi to offer new treatment options for patients suffering from conditions such as inflammatory bowel disease, where there remains a substantial unmet medical need.-Fineline Info & Tech